Our Services
Medical Information
Helpful Resources
Published on: 7/21/2026
GLP-1 Constipation: A Stepwise Management Protocol
GLP-1 receptor agonists (such as semaglutide, tirzepatide, and liraglutide) commonly slow gastric emptying and colonic motility, resulting in constipation for many users. Effective relief typically follows a stepwise protocol:
Optimal dosing, meal and medication timing, supportive measures, and red-flag symptoms (severe pain, vomiting, blood in stool, or no bowel movement beyond 5–7 days) all warrant close attention.
Because GLP-1 side effects can overlap with more serious conditions, it's worth clarifying what's actually driving your symptoms before choosing a treatment path. A free, instant, online symptom check can help you identify likely causes, flag urgent warning signs, and guide your next steps—whether that means adjusting your routine, trying an OTC remedy, or contacting your prescriber. It takes just a few minutes and could save you days of guesswork.
Reviewed for medical accuracy: 07/21/2026
Many patients taking GLP-1 receptor agonists (semaglutide, liraglutide, etc.) for diabetes or weight management report constipation. Clinical trials note constipation in up to 10% of users. While this side effect is common, it can become severe and impact your quality of life. Below is a stepwise, evidence-based protocol built on guidelines from the American Gastroenterological Association and peer-reviewed studies. It's designed to relieve constipation safely and effectively.
GLP-1 medications work by slowing gastric emptying and modulating gut motility to help you feel full longer. Unfortunately, that slowdown can extend to the colon:
Understanding this helps tailor remedies that both ease constipation and allow you to continue the benefits of your GLP-1 therapy.
Each step should be tried for 3–5 days before moving to the next. Always discuss changes with your healthcare provider.
Adequate fluid and fiber soften stool and promote regular bowel movements.
Movement stimulates colonic contractions.
If diet and exercise aren't enough, add a stool softener.
These draw water into the bowel, easing passage.
Use short-term only (up to 7 days) to avoid dependence.
If over-the-counter (OTC) options fail, prescription agents can help.
For refractory cases or alarm symptoms:
Constipation can sometimes signal a more serious problem. Contact a healthcare provider right away if you have:
If you're unsure about your symptoms or want personalized guidance, try Ubie's free AI-powered Constipation Symptom Checker to help determine the urgency of your situation and what steps to take next.
Constipation on GLP-1 therapy is common, but it doesn't have to derail your health goals. This stepwise approach—from hydration and fiber to prescription treatments—mirrors what I use in my own practice. Always start with lifestyle adjustments, then add OTC and, if needed, prescription therapies. If symptoms persist or you notice red flags, speak to your doctor promptly. Managing constipation effectively allows you to continue the benefits of GLP-1s while maintaining digestive comfort.
Disclaimer: This protocol is intended for general informational purposes only and does not substitute for personalized medical advice. Always speak to your healthcare provider before making changes to your treatment plan, especially if you experience severe or life-threatening symptoms.
(References)
* Frias JP, Nauck MA, Van Gaal L, et al. Management of gastrointestinal side effects associated with glucagon-like peptide-1 receptor agonists: a practical guide. *Front Endocrinol (Lausanne)*. 2023;14:1229712. doi:10.3389/fendo.2023.1229712
* Wilding JPH, Batterham RL, Calanna S, et al. Gastrointestinal adverse events with semaglutide: a review of current evidence and practical management strategies. *Diabetes Obes Metab*. 2023;25(4):947-956. doi:10.1111/dom.14922
* Davies M, Færch K, Jeppesen OK, et al. Managing gastrointestinal adverse events associated with GLP-1 receptor agonists for weight management. *Front Endocrinol (Lausanne)*. 2022;13:955282. doi:10.3389/fendo.2022.955282
* Horowitz M, Rayner CK, Jones KL, et al. GLP-1 receptor agonists and gastrointestinal motility: implications for the treatment of obesity and type 2 diabetes. *Lancet Diabetes Endocrinol*. 2020;8(10):809-822. doi:10.1016/S2213-8587(20)30282-4
* Buse JB, Dungan K, Gao L, et al. Practical guidance for managing gastrointestinal side effects of GLP-1 receptor agonists in patients with type 2 diabetes. *Diabetes Res Clin Pract*. 2022;184:109159. doi:10.1016/j.diabres.2022.109159
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.